CompletedNot Applicable

Assessing the Utility of Plasma ctHPVDNA for Anal Cancer Screening

United States104 participantsStarted 2024-04-03

Plain-language summary

The study is to test a liquid biopsy assay for screening and classifying anal dysplasia from blood.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Past or current anal HPV-positive population undergone anal dysplasia screening. * Control patients from the general population. Exclusion Criteria: * Not meeting inclusion criteria.

What they're measuring

Cancer Developmental Stage

Timeframe: Periprocedural

Trial details

NCT IDNCT06971276

SponsorMassachusetts Eye and Ear Infirmary

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2025-12-31

View on ClinicalTrials.gov More Anal Dysplasia trials